Latvia's €200 million Eurobond due 2008 Assigned 'BBB' Rating Nov 01

  • ID: 1833160
  • November 2001
  • Region: Latvia
  • Standard & Poors
1 of 3

LONDON (Standard & Poor's) Nov. 13, 2001--Standard & Poor's today assigned its triple-'B' senior unsecured debt rating to the Republic of Latvia's recent €200 million Eurobond maturing in 2008. The ratings on Latvia (local currency A-/Stable/A-2; foreign currency BBB/Positive/A-3) are supported by its: -- Track record of sound macroeconomic management, which is expected to continue in the foreseeable future. Latvia's fiscal flexibility is significant. General government debt to GDP is less than 20% and the general government is a small net external creditor (including government guarantees net public debt is estimated at less than 5% of exports in 2001). Monetary policy has been based on the Latvian lat's peg to the Special Drawing Right, maintaining inflation at low single-digit figures...

Companies mentioned in this report are:
- Latvia (Republic of)

Action: New Rating

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Note: Product cover images may vary from those shown
2 of 3

- Latvia (Republic of)

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.